- Cardiac surgeon
- Principal investigator clinical trials
- Numerous publications and scientific awards
- Graduate physicist
- CEO of STS Systemtechnik Electronic GmbH
- Serial Entrepeneur
- Experience in technical verification, clinical evaluation and patent matters
- Monitor for clinical studies on countless projects
- Previous technical experience at production and control
- Finance and Controlling
- Investor Relations
- Certified QMB
- Years of experience in development and QM
- Several decades of experience in the shock wave sector
- Master student of medical technology
- Student employee
- Student employee
- Student employee
- Serial Entrepeneur
- years of experience in quality management
- Cooperation and consulting of medical device companies all over the world
- Leiter Universitätsklinik für Herzchirurgie
- Medizinische Universität Innsbruck
Avenns Medical is 90% owner of STS Systemtechnik Electronic GmbH since fall 2022 and has thus secured in-house production for the long term.
- Joseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair in Cardiovascular Disease Research
- Department of Cardiovascular Sciences Chair
- Academic Institute Full Member
- Research Institute Director
- Center for Cardiovascular Regeneration Medical Director
- Center for RNA Therapeutics Houston Methodist
- Paul Yock is the Martha Meier Weiland Professor of Medicine, Emeritus and founding co-chair of Stanford’s Department of Bioengineering.
- Founding Director of the Stanford Byers Center for Biodesign.
- Is known for his work in inventing, developing, and testing new devices, including the Rapid Exchange ™ stenting and balloon angioplasty system, which is now the primary system in use worldwide.
- He also invented ultrasound imaging and founded Cardiovascular Imaging Systems (CVIS).
- Oliver Ginthör studied business administration and law in Vienna, Angers (France) and China.
- Tax consultant
- Member of the board of numerous private foundations
- Managing director and supervisory board member in various companies
- Lecturer and author of numerous publications
- Cardiac surgeon
- Principal investigator clinical trials
- Numerous publications and scientific awards
- Graduate physicist
- CEO of STS Systemtechnik Electronic GmbH
- Serial Entrepeneur
- Experience in technical verification, clinical evaluation and patent matters
- Monitor for clinical studies on countless projects
- Previous technical experience at production and control
- Business Development and Communications
- Fundraising
- extensive experience in human resources and general management
- Certified QMB
- Years of experience in development and QM
- Since several decades in the shock wave sector
- Master student of medical technology
- Master student of medical technology
- Project staff USA
- Student employee
- Student employee
- Serial Entrepeneur
- years of experience in quality management
- Cooperation and consulting of medical device companies all over the world
- Leiter Universitätsklinik für Herzchirurgie
- Medizinische Universität Innsbruck
- Joseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair in Cardiovascular Disease Research
- Department of Cardiovascular Sciences Chair
- Academic Institute Full Member
- Research Institute Director
- Center for Cardiovascular Regeneration Medical Director
- Center for RNA Therapeutics Houston Methodist
- Paul Yock is the Martha Meier Weiland Professor of Medicine, Emeritus and founding co-chair of Stanford’s Department of Bioengineering.
- Founding Director of the Stanford Byers Center for Biodesign.
- Is known for his work in inventing, developing, and testing new devices, including the Rapid Exchange ™ stenting and balloon angioplasty system, which is now the primary system in use worldwide.
- He also invented ultrasound imaging and founded Cardiovascular Imaging Systems (CVIS).
- Oliver Ginthör studied business administration and law in Vienna, Angers (France) and China.
- Tax consultant
- Member of the board of numerous private foundations
- Managing director and supervisory board member in various companies
- Lecturer and author of numerous publications
2013
Johannes Holfeld (Cardiac Surgeon) and Christian Dorfmüller (Physicist and Engineer) decided to develop shockwave therapy for heart regeneration encouraged by remarkable pre-clinical results.
2014
CAST, the Center of Academic Spin-offs Tyrol, an institution of the Medical University of Innsbruck and the government of Tyrol funded the project (applicator for use during open heart surgery)
2015
The team was awarded the Life Science Cluster Award of the Standortagentur Tirol for its development of a cardiac shockwave applicator.
2015
Winning the AdventureX Founders Competition in
Tyrol, Austria
2016
Founding of HeaRT Regeneration Technologies GmbH by the cardiac surgeons Johannes Holfeld, Michael Grimm and physicist Christian Dorfmüller.
2016
Based on a market analysis by the Boston Consulting Group the Tyrolean Business Angel GmbH joined the newly founded company as a lead investor.
2017
HeaRT Regeneration Technologies GmbH receives pre-seed funding from AWS (Austrian Wirtschaftsservice - promotional bank of the Austrian federal government).
2018
HeaRT starts manufacturing of the cardiac shockwave probes. Additional private investors joined the company.
2018
HeaRT Regeneration Technologies GmbH receives seed funding from AWS (Austrian Wirtschaftsservice - promotional bank of the Austrian federal government).
2019
HeaRT Regeneration Technologies GmbH receives funding from FFG (Forschungsförderungsgesellschaft, Austrian Research Promotion Agency) to further develop its advanced products for new indications.
2019
The clinical trial CAST-HF started treating the first human patients directly on the heart at Medical University of Innsbruck, Austria (www.cast-trial.com).
2022
At the end of 2022, we acquired our development partner in Ravensburg, Germany, thus securing one of the crucial areas for our company, the development of our tabletop devices, and bringing it in-house. This acquisition allows us to have more control over the development process, streamline operations, and ultimately enhance the quality of our products.
2023
Q2 We have acquired a new office space to accommodate our growth and also to facilitate the in-house production of our shockwave device. We have successfully transitioned to producing the transducer completely in-house, allowing for greater control over the manufacturing process and ensuring the highest quality of our products.
2023
Q4 CE mark approval of the shockwave device.